PrEP

;

Questions for Dr. David J. Weldon on his nomination to become CDC director

Feb 27, 2025

As the Committee considers the nomination of David J. Welson, M.D. to serve as Director of the Centers for Disease Control and Prevention, the HIV+Hepatitis Policy Institute urges you to ensure the nominee will uphold a stalwart commitment to a comprehensive healthcare system that includes implementation of robust disease prevention efforts critical in making American healthier again and in ending the chronic diseases of HIV and hepatitis. These are suggested questions for Dr. Weldon concerning his support for 1) CDC HIV prevention programs instrumental in the Ending the HIV Epidemic Initiative (EHE), 2) increasing access to PrEP medications which prevent HIV transmission, and 3) CDC programs addressing viral hepatitis.

read more

Letter urging Governor Youngkin to veto VA HB1724 creating a PDAB

Feb 24, 2025

While we share a commitment to addressing the high cost of prescription drugs, we have significant concerns with H.B. 1724 that creates a Prescription Drug Affordability Board (PDAB). We believe it will not translate into lower drug costs for patients and may dampen future drug development. Access to and affordability of the latest drugs are especially critical for patients living with HIV, hepatitis, cancer, and rare diseases. People with HIV and hepatitis B rely on drug treatments that they must take for the rest of their lives, while people with hepatitis C can be cured of their disease in as little as 8 to 12 weeks. We also now have medications that prevent HIV.

read more

Questions for Mehmet Oz, M.D. for his nomination to lead CMS

Feb 10, 2025

As the Committee considers the nomination of Mehmet C. Oz, M.D. to serve as CMS Administrator, the HIV+Hepatitis Policy Institute urges you to ensure the nominee will uphold a stalwart commitment to a comprehensive healthcare system that includes a robust private insurance market, along with strong Medicaid and Medicare programs. All are critical to making American healthier again and in ending the chronic diseases of HIV and hepatitis. Please find attached suggested questions for Dr. Oz concerning 1) a federal court decision regarding copay assistance for prescription drugs, 2) preventive services coverage under the ACA, 3) private insurance prescription drug coverage and affordability policies, and 4) the Medicare Part D six protected classes of prescription drugs.

read more

Maryland Senate letter in opposition to to SB0357 expanding the authority of the Prescription Drug Affordability Board

Feb 4, 2025

While we share a commitment to addressing the high cost of prescription drugs, we have significant concerns with SB0357 that expands the authority of the Prescription Drug Affordability Board (PDAB). We believe it will not translate into lower drug costs for patients and may dampen future drug development. Access to and affordability of the latest drugs are especially critical for patients living with HIV, hepatitis, cancer, and rare diseases. People with HIV and hepatitis B rely on drug treatments that they must take for the rest of their lives, while people with hepatitis C can be cured of their disease in as little as 8 to 12 weeks. We also now have medications that prevent HIV.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest